Therapeutic approaches to protein-misfolding diseases (Q34285075)

1 August 2017

1 reference

title

Therapeutic approaches to protein-misfolding diseases (English)

1 reference

1 August 2017

1

Fred E Cohen

1 reference

1 August 2017

Jeffery W Kelly

2

1 reference

PubMed ID

14685252

1 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

1 August 2017

1 reference

1 August 2017

426

1 reference

1 August 2017

905-909

1 reference

1 August 2017

6968

1 reference

https://scigraph.springernature.com/pub.10.1038/nature02265

1 August 2017

0 references

cites work

Principles that govern the folding of protein chains

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Alpha1-antitrypsin deficiency--a model for conformational diseases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Amyloid fibrillogenesis: themes and variations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Alternative conformations of amyloidogenic proteins govern their behavior

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Ligands act as pharmacological chaperones and increase the efficiency of delta opioid receptor maturation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Therapeutic strategies for human amyloid diseases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Potent inhibition of scrapie prion replication in cultured cells by bis-acridines

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Antibodies inhibit prion propagation and clear cell cultures of prion infectivity

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Monoclonal antibodies inhibit prion replication and delay the development of prion disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Anti-aggregating antibodies, a new approach towards treatment of conformational diseases

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another protein

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

The antisense approach in amyloid light chain amyloidosis: identification of monoclonal Ig and inhibition of its production by antisense oligonucleotides in in vitro and in vivo models

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Peptide inhibitors of beta amyloid aggregation

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Amyloid as a natural product

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Secretase as a target for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Beta-secretase (BACE) as a drug target for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocol

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Amyloid fibrils from muscle myoglobin

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Folding of prion protein to its native alpha-helical conformation is under kinetic control

1 reference

https://api.crossref.org/works/10.1038%2FNATURE02265

7 January 2021

Identifiers

DOI

10.1038/NATURE02265

1 reference

PubMed ID

14685252

Dimensions Publication ID

1 August 2017

0 references

1 reference

PubMed ID

14685252